Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.22M | -1.25M | -1.21M | -965.40K | -672.30K |
| Total Depreciation and Amortization | 299.50K | 261.00K | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.80K | 86.10K | 37.50K | 54.10K | 38.60K |
| Change in Net Operating Assets | -132.80K | -147.60K | 31.20K | -8.90K | -113.20K |
| Cash from Operations | -975.00K | -1.05M | -1.14M | -920.50K | -747.10K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -150.00K | -150.00K | -- | -- | -- |
| Cash from Investing | -150.00K | -150.00K | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 357.00K | 357.00K | 347.50K | 347.50K | 347.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 357.00K | 357.00K | 347.50K | 347.50K | 347.50K |
| Foreign Exchange rate Adjustments | 56.50K | 52.60K | -700.00 | 2.10K | -52.50K |
| Miscellaneous Cash Flow Adjustments | -22.90K | -22.90K | -22.90K | 0.00 | 0.00 |
| Net Change in Cash | -734.40K | -815.50K | -814.20K | -570.80K | -452.10K |